Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 3/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL3729146 | 0.93 | CYP2D6 (0.41) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL12189845 | 0.89 | CYP2D6 (0.38) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| 1,4-Butanediol SCHEMBL3743493 | 0.89 | FFAR1 (0.38) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| Propylene Glycol SCHEMBL3730785 | 0.85 | TDP1 (0.39) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| Di(Hydroxyethyl)Ether SCHEMBL3728469 | 0.85 | TSHR (0.39) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| Tetraethylene Glycol SCHEMBL3746474 | 0.84 | MEN1 (0.41) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| Triethylene Glycol SCHEMBL3731014 | 0.84 | MEN1 (0.41) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL3738552 | 0.81 | CYP4F2 (0.41) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL3736963 | 0.81 | CYP4F2 (0.41) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL2468613 | 0.78 | TDP1 (0.42) | TSHRALDH1A1CPT2FFAR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421358-B2 | Polymer film, preparation method thereof, and polymer film laminate comprising the same | LG CHEM, LTD. (KR) | 2025-09-23 | — | — | US | claimed |
| WO-2024233640-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | HEMOSHEAR THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | claimed |
| US-20240142475-A1 | COMPOSITIONS AND METHODS FOR THE DETECTION OF TUBERCULOSIS | WASHINGTON UNIVERSITY | 2024-05-02 | — | — | US | claimed |
| US-20240115566-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST JUDE CHILDRENS RES HOSPITAL INC (US) | 2024-04-11 | — | — | US | claimed |
| EP-4319746-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | claimed |
| EP-4262814-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | St. Jude Children's Research Hospital, Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| US-20230313241-A1 | RECOMBINANT MICROORGANISM FOR PRODUCING POLY(3- HYDROXYBUTYRATE-CO-3-HYDROXYVALERATE) | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-10-05 | — | — | US | claimed |
| US-20230089009-A1 | Polymer Film, Preparation Method Thereof, and Polymer Film Laminate Comprising the Same | LG CHEM, LTD. (KR) | 2023-03-23 | — | — | US | claimed |
| EP-4082783-A1 | POLYMER FILM, PREPARATION METHOD THEREOF, AND POLYMER FILM LAMINATE COMPRISING SAME | Lg Chem, Ltd. (KR) | 2022-11-02 | — | — | EP | claimed |
| US-20140141482-A1 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA North America S.á r.l. (US) | 2014-05-22 | — | — | US | claimed |
| WO-2013188546-A2 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA TECHNOLOGIES S.À.R.L. (CH) | 2013-12-19 | — | — | WO | claimed |
| US-20130189753-A1 | METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE | INVISTA NORTH AMERICA S.A R.L. (US) | 2013-07-25 | — | — | US | claimed |
| WO-2013082542-A2 | METHODS FOR BIOSYNTHESIZING 1,3BUTADIENE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2013-06-06 | — | — | WO | claimed |
| EP-2501826-A1 | NUTRIGENETIC BIOMARKERS FOR OBESITY AND TYPE 2 DIABETES | MAS-Metabolic Analytical Services Oy (FI) | 2012-09-26 | — | — | EP | claimed |
| US-20120225047-A1 | NUTRIGENETIC BIOMARKERS FOR OBESITY AND TYPE 2 DIABETES | MAS-METABOLIC ANALYTICAL SERVICES OY (FI) | 2012-09-06 | — | — | US | claimed |
| WO-2011058232-A1 | NUTRIGENETIC BIOMARKERS FOR OBESITY AND TYPE 2 DIABETES | MAS-METABOLIC ANALYTICAL SERVICES OY (FI) | 2011-05-19 | — | — | WO | claimed |
| CN-1809368-B | Compositions and methods for controlling insects | TYRATECH INC | 2011-02-09 | — | — | CN | claimed |
| CN-101897342-A | Preparation of insecticide solution and application thereof | BESTCHEM CO LTD GUIYANG | 2010-12-01 | — | — | CN | claimed |
| US-4572740-A | Citric acid esters as blowing and nucleating agents in the processing plastics | BOEHRINGER INGELHEIM KG (DE) | 1986-02-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | MMAB, OTC, ME2 | CYP2C19 1899/4885HIF1A 2266/4885CYP2D6 1644/4885 |
| US-20240115566-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, ACADM | CYP2C19 2550/4885HIF1A 2181/4885CYP2D6 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.